FLABRA, frontline approach for BRCA testing in an ovarian cancer population: a Latin America epidemiologic study
FLABRA evaluated the prevalence of mutations, genetic counseling and management approaches in patients with ovarian cancer in Latin America. Patients with ovarian cancer from six Latin-American countries were enrolled. Tumor samples were tested for mutations ( ). In cases with , blood samples were...
Gespeichert in:
| Veröffentlicht in: | Future oncology (London, England) England), 2021-05, Vol.17 (13), p.1601-1609 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1609 |
|---|---|
| container_issue | 13 |
| container_start_page | 1601 |
| container_title | Future oncology (London, England) |
| container_volume | 17 |
| creator | Giornelli, Gonzalo Gallardo, Dolores Hegg, Roberto Abuin, Gonzalo Gomez La Vega, Maximo De Lim-Law, Maria Caceres, Valeria Trujillo, Lina Pilar Estevez-Diz, Maria Del Pacheco, Cristian Sganga, Leonardo Goncalves, Susana |
| description | FLABRA evaluated the prevalence of
mutations, genetic counseling and management approaches in patients with ovarian cancer in Latin America.
Patients with ovarian cancer from six Latin-American countries were enrolled. Tumor samples were tested for
mutations (
). In cases with
, blood samples were analyzed to determine germline versus somatic mutations. Medical records were reviewed for counseling approach and treatment plan.
From 472 patients enrolled, 406 samples yielded conclusive results: 282 were
wild-type (
), 115 were
and nine were variants of uncertain significance. In total, 110/115 were tested for germline mutations (77 germline and 33 somatic).
Tumor testing to identify mutations in
in ovarian cancer can help optimize treatment choices, meaning fewer patients require germline testing and genetic counseling, a scant resource in Latin America.
NCT02984423 (ClinicalTrials.gov). |
| doi_str_mv | 10.2217/fon-2020-1152 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2476565098</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2476565098</sourcerecordid><originalsourceid>FETCH-LOGICAL-c332t-3a87a1596bcf1a39eeaeb42d1bc4900a9c14dd2a7ff607a5c823bed21c7a7d113</originalsourceid><addsrcrecordid>eNo9kM1KxDAUhYMojn9Lt5KlC6v5azN11xkcFQqC6LrcpqlG2qSTtIJv47P4ZGaY0dU5i4_DvR9C55RcM0blTetswggjCaUp20NHVAqRzDmh-7ELmSdZlosZOg7hgxAheUoO0YxzQdM8Z0dovSqLxXNxhVvv7NgZqzEMg3eg3nHrPF48Lws86jAa-4aNxWCx-wRvYiqwSns8uGHqYDTO3mL4-S5jtbjotTcKsB5Mo3vjOvdmFA7j1HydooMWuqDPdnmCXld3L8uHpHy6f1wWZaI4Z2PCYS4hHpnVqqXAc61B14I1tFYiJwRyRUXTMJBtmxEJqZozXuuGUSVBNpTyE3S53Y3frKf4QdWboHTXgdVuChUTMkuzlOTziCZbVHkXgtdtNXjTg_-qKKk2lqtoudpYrjaWI3-xm57qXjf_9J9W_gvx43nQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2476565098</pqid></control><display><type>article</type><title>FLABRA, frontline approach for BRCA testing in an ovarian cancer population: a Latin America epidemiologic study</title><source>PubMed Central</source><creator>Giornelli, Gonzalo ; Gallardo, Dolores ; Hegg, Roberto ; Abuin, Gonzalo Gomez ; La Vega, Maximo De ; Lim-Law, Maria ; Caceres, Valeria ; Trujillo, Lina ; Pilar Estevez-Diz, Maria Del ; Pacheco, Cristian ; Sganga, Leonardo ; Goncalves, Susana</creator><creatorcontrib>Giornelli, Gonzalo ; Gallardo, Dolores ; Hegg, Roberto ; Abuin, Gonzalo Gomez ; La Vega, Maximo De ; Lim-Law, Maria ; Caceres, Valeria ; Trujillo, Lina ; Pilar Estevez-Diz, Maria Del ; Pacheco, Cristian ; Sganga, Leonardo ; Goncalves, Susana</creatorcontrib><description> FLABRA evaluated the prevalence of
mutations, genetic counseling and management approaches in patients with ovarian cancer in Latin America.
Patients with ovarian cancer from six Latin-American countries were enrolled. Tumor samples were tested for
mutations (
). In cases with
, blood samples were analyzed to determine germline versus somatic mutations. Medical records were reviewed for counseling approach and treatment plan.
From 472 patients enrolled, 406 samples yielded conclusive results: 282 were
wild-type (
), 115 were
and nine were variants of uncertain significance. In total, 110/115 were tested for germline mutations (77 germline and 33 somatic).
Tumor testing to identify mutations in
in ovarian cancer can help optimize treatment choices, meaning fewer patients require germline testing and genetic counseling, a scant resource in Latin America.
NCT02984423 (ClinicalTrials.gov).</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon-2020-1152</identifier><identifier>PMID: 33415992</identifier><language>eng</language><publisher>England</publisher><ispartof>Future oncology (London, England), 2021-05, Vol.17 (13), p.1601-1609</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c332t-3a87a1596bcf1a39eeaeb42d1bc4900a9c14dd2a7ff607a5c823bed21c7a7d113</citedby><cites>FETCH-LOGICAL-c332t-3a87a1596bcf1a39eeaeb42d1bc4900a9c14dd2a7ff607a5c823bed21c7a7d113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33415992$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Giornelli, Gonzalo</creatorcontrib><creatorcontrib>Gallardo, Dolores</creatorcontrib><creatorcontrib>Hegg, Roberto</creatorcontrib><creatorcontrib>Abuin, Gonzalo Gomez</creatorcontrib><creatorcontrib>La Vega, Maximo De</creatorcontrib><creatorcontrib>Lim-Law, Maria</creatorcontrib><creatorcontrib>Caceres, Valeria</creatorcontrib><creatorcontrib>Trujillo, Lina</creatorcontrib><creatorcontrib>Pilar Estevez-Diz, Maria Del</creatorcontrib><creatorcontrib>Pacheco, Cristian</creatorcontrib><creatorcontrib>Sganga, Leonardo</creatorcontrib><creatorcontrib>Goncalves, Susana</creatorcontrib><title>FLABRA, frontline approach for BRCA testing in an ovarian cancer population: a Latin America epidemiologic study</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description> FLABRA evaluated the prevalence of
mutations, genetic counseling and management approaches in patients with ovarian cancer in Latin America.
Patients with ovarian cancer from six Latin-American countries were enrolled. Tumor samples were tested for
mutations (
). In cases with
, blood samples were analyzed to determine germline versus somatic mutations. Medical records were reviewed for counseling approach and treatment plan.
From 472 patients enrolled, 406 samples yielded conclusive results: 282 were
wild-type (
), 115 were
and nine were variants of uncertain significance. In total, 110/115 were tested for germline mutations (77 germline and 33 somatic).
Tumor testing to identify mutations in
in ovarian cancer can help optimize treatment choices, meaning fewer patients require germline testing and genetic counseling, a scant resource in Latin America.
NCT02984423 (ClinicalTrials.gov).</description><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNo9kM1KxDAUhYMojn9Lt5KlC6v5azN11xkcFQqC6LrcpqlG2qSTtIJv47P4ZGaY0dU5i4_DvR9C55RcM0blTetswggjCaUp20NHVAqRzDmh-7ELmSdZlosZOg7hgxAheUoO0YxzQdM8Z0dovSqLxXNxhVvv7NgZqzEMg3eg3nHrPF48Lws86jAa-4aNxWCx-wRvYiqwSns8uGHqYDTO3mL4-S5jtbjotTcKsB5Mo3vjOvdmFA7j1HydooMWuqDPdnmCXld3L8uHpHy6f1wWZaI4Z2PCYS4hHpnVqqXAc61B14I1tFYiJwRyRUXTMJBtmxEJqZozXuuGUSVBNpTyE3S53Y3frKf4QdWboHTXgdVuChUTMkuzlOTziCZbVHkXgtdtNXjTg_-qKKk2lqtoudpYrjaWI3-xm57qXjf_9J9W_gvx43nQ</recordid><startdate>202105</startdate><enddate>202105</enddate><creator>Giornelli, Gonzalo</creator><creator>Gallardo, Dolores</creator><creator>Hegg, Roberto</creator><creator>Abuin, Gonzalo Gomez</creator><creator>La Vega, Maximo De</creator><creator>Lim-Law, Maria</creator><creator>Caceres, Valeria</creator><creator>Trujillo, Lina</creator><creator>Pilar Estevez-Diz, Maria Del</creator><creator>Pacheco, Cristian</creator><creator>Sganga, Leonardo</creator><creator>Goncalves, Susana</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202105</creationdate><title>FLABRA, frontline approach for BRCA testing in an ovarian cancer population: a Latin America epidemiologic study</title><author>Giornelli, Gonzalo ; Gallardo, Dolores ; Hegg, Roberto ; Abuin, Gonzalo Gomez ; La Vega, Maximo De ; Lim-Law, Maria ; Caceres, Valeria ; Trujillo, Lina ; Pilar Estevez-Diz, Maria Del ; Pacheco, Cristian ; Sganga, Leonardo ; Goncalves, Susana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c332t-3a87a1596bcf1a39eeaeb42d1bc4900a9c14dd2a7ff607a5c823bed21c7a7d113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giornelli, Gonzalo</creatorcontrib><creatorcontrib>Gallardo, Dolores</creatorcontrib><creatorcontrib>Hegg, Roberto</creatorcontrib><creatorcontrib>Abuin, Gonzalo Gomez</creatorcontrib><creatorcontrib>La Vega, Maximo De</creatorcontrib><creatorcontrib>Lim-Law, Maria</creatorcontrib><creatorcontrib>Caceres, Valeria</creatorcontrib><creatorcontrib>Trujillo, Lina</creatorcontrib><creatorcontrib>Pilar Estevez-Diz, Maria Del</creatorcontrib><creatorcontrib>Pacheco, Cristian</creatorcontrib><creatorcontrib>Sganga, Leonardo</creatorcontrib><creatorcontrib>Goncalves, Susana</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giornelli, Gonzalo</au><au>Gallardo, Dolores</au><au>Hegg, Roberto</au><au>Abuin, Gonzalo Gomez</au><au>La Vega, Maximo De</au><au>Lim-Law, Maria</au><au>Caceres, Valeria</au><au>Trujillo, Lina</au><au>Pilar Estevez-Diz, Maria Del</au><au>Pacheco, Cristian</au><au>Sganga, Leonardo</au><au>Goncalves, Susana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>FLABRA, frontline approach for BRCA testing in an ovarian cancer population: a Latin America epidemiologic study</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2021-05</date><risdate>2021</risdate><volume>17</volume><issue>13</issue><spage>1601</spage><epage>1609</epage><pages>1601-1609</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract> FLABRA evaluated the prevalence of
mutations, genetic counseling and management approaches in patients with ovarian cancer in Latin America.
Patients with ovarian cancer from six Latin-American countries were enrolled. Tumor samples were tested for
mutations (
). In cases with
, blood samples were analyzed to determine germline versus somatic mutations. Medical records were reviewed for counseling approach and treatment plan.
From 472 patients enrolled, 406 samples yielded conclusive results: 282 were
wild-type (
), 115 were
and nine were variants of uncertain significance. In total, 110/115 were tested for germline mutations (77 germline and 33 somatic).
Tumor testing to identify mutations in
in ovarian cancer can help optimize treatment choices, meaning fewer patients require germline testing and genetic counseling, a scant resource in Latin America.
NCT02984423 (ClinicalTrials.gov).</abstract><cop>England</cop><pmid>33415992</pmid><doi>10.2217/fon-2020-1152</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-6694 |
| ispartof | Future oncology (London, England), 2021-05, Vol.17 (13), p.1601-1609 |
| issn | 1479-6694 1744-8301 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2476565098 |
| source | PubMed Central |
| title | FLABRA, frontline approach for BRCA testing in an ovarian cancer population: a Latin America epidemiologic study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T18%3A36%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=FLABRA,%20frontline%20approach%20for%20BRCA%20testing%20in%20an%20ovarian%20cancer%20population:%20a%C2%A0Latin%20America%20epidemiologic%20study&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Giornelli,%20Gonzalo&rft.date=2021-05&rft.volume=17&rft.issue=13&rft.spage=1601&rft.epage=1609&rft.pages=1601-1609&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon-2020-1152&rft_dat=%3Cproquest_cross%3E2476565098%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2476565098&rft_id=info:pmid/33415992&rfr_iscdi=true |